Magainin Pharm (MAGN) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Magainin Pharm (MAGN)

MAGN 8.890

+2.2%

Nov 7 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: WWS who wrote (115)	3/8/1998 4:01:00 PM
From: Shlepper	Read Replies (1) of 233

Bill, It's nice having you on this thread... Based upon everything I've heard, Zaslof is excited about the potential found in the squalamine, and would probably prefer questions on this. As far as current business is concerned, Cytolex, as you mentioned may have some competition in the diabetic ulcer arena, but will hopefully realize reasonable income from this. The question regarding Cytolex relates to the wound healing. the reported test results indicated that the wound healing properties at all concentrations were significantly less successful than Oraflex...but that further tests of the applicability of the Cytolex for wound healing were being investigated...(anyway, that's how I remember the reports). The most important question to Mike may be the progress and prognosis for Cytolex for other applications such as wound healing - since this is where the bigger bucks may come... Good Luck, Shep

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next